Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5285119 and vasopressin fMRI mechanism study in healthy male volunteers
NL-OMON42183Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of balovaptan and vasopressin in Autism Spectrum Disorder (ASD) and anxiety disorder (2 cohorts), sponsored by Roche. Primary endpoints: BOLD fMRI changes during face matching task, BOLD fMRI changes during emotional face processing task and 1 more. Started Aug 2014; status: active, not recruiting.
02
Drugs
balovaptanvasopressin
03
Conditions
Autism Spectrum Disorder (ASD)anxiety disorder
Beyond the preview
Go deeper on NL-OMON42183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42183.